Didactics-Primary vs Interval Debulking for Advanced Ovarian Cancer

Video Transcription

Video Summary

In this video, the speaker discusses the challenges of treating advanced ovarian cancer. The speaker highlights that ovarian cancer is the sixth most commonly diagnosed cancer among women worldwide and is known to be very lethal due to its advanced stage presentation in most cases. The current standard treatment involves a combination of surgery and chemotherapy. The speaker emphasizes the importance of achieving optimal debulking during surgery, where minimal or no residual disease is left behind. The survival rates are shown to significantly improve with greater debulking. The speaker discusses the option of neoadjuvant chemotherapy, where patients receive chemotherapy prior to surgery, and its effectiveness in achieving optimal debulking. Several studies comparing neoadjuvant chemotherapy and primary debulking surgery are presented, highlighting similar survival rates, but with potentially less morbidity in neoadjuvant chemotherapy. The speaker concludes by discussing the use of neoadjuvant chemotherapy in other ovarian cancers, such as germ cell tumors, and suggests the possibility of publishing a case report on neoadjuvant chemotherapy experiences.

Asset Subtitle

Linus Chuang
January 2020

Keywords

advanced ovarian cancer

surgery

chemotherapy

optimal debulking

neoadjuvant chemotherapy

survival rates